MARKET

CYCC

CYCC

Cyclacel Pharma
NASDAQ
2.240
-0.010
-0.44%
Opening 11:09 05/22 EDT
OPEN
2.235
PREV CLOSE
2.250
HIGH
2.240
LOW
2.140
VOLUME
8.45K
TURNOVER
0
52 WEEK HIGH
13.20
52 WEEK LOW
1.300
MARKET CAP
3.28M
P/E (TTM)
-0.1019
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CYCC last week (0513-0517)?
Weekly Report · 2d ago
CYCC Stock Earnings: Cyclacel Pharmaceuticals Beats EPS for Q1 2024
Investorplace · 05/15 00:54
Cyclacel Pharmaceuticals, Inc. Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended March 31, 2024
Press release · 05/14 23:41
Cyclacel Pharma: Quarterly report
Press release · 05/14 22:33
Cyclacel Pharmaceuticals GAAP EPS of -$2.27 beats by $2.48
Seeking Alpha · 05/14 20:53
Cyclacel Pharmaceuticals Q1 EPS $(2.27) Beats $(4.74) Estimate, Sales $29.00K
Benzinga · 05/14 20:24
APP, MGNX and CYCC among pre-market losers
On the Move APP, MGNX and CYCC among pre-market losers. Augmedix (AUGX) -38% reports Q1 results. Inotiv (NOTV) will report fiscal 2024 second quarter financial results on May 15, 2024.
Seeking Alpha · 05/14 12:25
Notable earnings after Tuesday's close
Major earnings expected after the bell on Tuesday include: Oxford Lane Capital Corp. And Seadrill Limited. Other major earnings slated for release after Tuesday's close include: Canoo and Canoo. The full earnings season calendar can be found at Seeking Alpha's Earnings season calendar.
Seeking Alpha · 05/13 21:35
More
About CYCC
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.

Webull offers Cyclacel Pharmaceuticals Inc stock information, including NASDAQ: CYCC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYCC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CYCC stock methods without spending real money on the virtual paper trading platform.